Antares Pharma, Inc. (ATRS) SEC Filing 8-K Material Event for the period ending Wednesday, June 26, 2019

SEC Filings

Antares Pharma, Inc.

CIK: 1016169 Ticker: ATRS

View differences made from one to another to evaluate Antares Pharma, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Antares Pharma, Inc..


Assess how Antares Pharma, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Antares Pharma, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Antares Pharma, Inc. provided additional information to their SEC Filing as exhibits

Ticker: ATRS
CIK: 1016169
Form Type: 8-K Corporate News
Accession Number: 0001564590-19-023664
Submitted to the SEC: Thu Jun 27 2019 8:00:38 AM EST
Accepted by the SEC: Thu Jun 27 2019
Period: Wednesday, June 26, 2019
Industry: Surgical And Medical Instruments And Apparatus
  1. Ending Agreement
  2. Financial Exhibit
  3. New Agreement
  4. New Financial Obligation
  5. Regulated Disclosure

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: